Brind.
  1. Amgen, Pfizer, and Celltrion are key players poised for rapid expansion in the biosimilars market in the US.
  2. Regulatory settlements and investment targets are driving biosimilar launches and facility expansion in the US.

Biocon is showing signs of a bullish technical breakout from its consolidation phase, with trading targets set above Rs 400.

1 report, 1 independent Updated Jun 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Biocon is showing signs of a bullish technical breakout from its consolidation phase, with trading targets set above Rs 400.

Who's involved

What this event is mainly about
Biocon

Keep exploring

Part of

Regulatory settlements and investment targets are driving biosimilar launches and facility expansion in the US. All 1 developments

Within Amgen, Pfizer, and Celltrion are key players poised for rapid expansion in the biosimilars market in the US.

The entities involved

  • Biocon

    an Indian biopharmaceutical company

    Nothing else this week.

Coverage

Newest first; wire copies grouped